Drug Trial Radar · NCT04762602
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
42
Actual
Start
Feb 28, 2021
Primary completion
Feb 27, 2025
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
Conditions
- Isocitrate Dehydrogenase Gene Mutation
Interventions
HMPL-306Drug
Administered orally QD in a 28-day continuous dosing treatment cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Recommended Phase 2 Dose (RP2D) of HMPL-306Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
- Part 1: Number of Patients With Dose-limiting Toxicities (DLTs)Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1
- Parts 1 and 2: Number of Patients With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 43 months for Part 1
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Sarcoma Oncology Research Center
Santa Monica, California
Emory University
Atlanta, Georgia
University of Iowa
Iowa City, Iowa
University of Kentucky
Lexington, Kentucky
Thomas Jefferson University
Philadelphia, Pennsylvania
UPMC Hillman Cancer
Pittsburgh, Pennsylvania
Houston Methodist
Houston, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Hospital de la Santa creu i Sant Pau
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.